Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National ...

Linfoma no Hodgkin en adultos: Tratamiento (PDQ®) - National Cancer Institute
35. Czuczman MS, Weaver R, Alkuzweny B, et al.: Prolonged clinical and molecular remission in patients with
low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year
follow-up. J Clin Oncol 22 (23): 4711-6, 2004. [PUBMED Abstract]
36. Hainsworth JD, Litchy S, Morrissey LH, et al.: Rituximab plus short-duration chemotherapy as first-line
treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research
Network. J Clin Oncol 23 (7): 1500-6, 2005. [PUBMED Abstract]
37. Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus
CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin
Oncol 22 (13): 2654-61, 2004. [PUBMED Abstract]
38. Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine,
cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as
compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:
results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104
(10): 3064-71, 2004. [PUBMED Abstract]
39. Whelan JS, Davis CL, Rule S, et al.: Fludarabine phosphate for the treatment of low grade lymphoid
malignancy. Br J Cancer 64 (1): 120-3, 1991. [PUBMED Abstract]
40. Solal-Céligny P, Brice P, Brousse N, et al.: Phase II trial of fludarabine monophosphate as first-line
treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des
Lymphomes de l'Adulte. J Clin Oncol 14 (2): 514-9, 1996. [PUBMED Abstract]
41. Saven A, Emanuele S, Kosty M, et al.: 2-Chlorodeoxyadenosine activity in patients with untreated, indolent
non-Hodgkin's lymphoma. Blood 86 (5): 1710-6, 1995. [PUBMED Abstract]
42. Fridrik MA, Jäger G, Kienzer HR, et al.: Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2
h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma. Eur J
Cancer 34 (10): 1560-4, 1998. [PUBMED Abstract]
43. Peterson BA, Petroni GR, Frizzera G, et al.: Prolonged single-agent versus combination chemotherapy in
indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21 (1): 5-15,
2003. [PUBMED Abstract]
44. Robinson KS, Williams ME, van der Jagt RH, et al.: Phase II multicenter study of bendamustine plus
rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol
26 (27): 4473-9, 2008. [PUBMED Abstract]
45. Hoppe RT, Kushlan P, Kaplan HS, et al.: The treatment of advanced stage favorable histology non-
Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy,
combination chemotherapy, and whole body irradiation. Blood 58 (3): 592-8, 1981. [PUBMED Abstract]
46. Hochster H, Weller E, Gascoyne RD, et al.: Maintenance rituximab after cyclophosphamide, vincristine,
and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the
randomized phase III ECOG1496 Study. J Clin Oncol 27 (10): 1607-14, 2009. [PUBMED Abstract]
47. Anderson T, DeVita VT Jr, Simon RM, et al.: Malignant lymphoma. II Prognostic factors and response to
treatment of 473 patients at the National Cancer Institute. Cancer 50 (12): 2708-21, 1982. [PUBMED Abstract]
48. Longo DL, Young RC, Hubbard SM, et al.: Prolonged initial remission in patients with nodular mixed
lymphoma. Ann Intern Med 100 (5): 651-6, 1984. [PUBMED Abstract]
49. Dana BW, Dahlberg S, Nathwani BN, et al.: Long-term follow-up of patients with low-grade malignant
lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11 (4):
644-51, 1993. [PUBMED Abstract]
50. Tsimberidou AM, McLaughlin P, Younes A, et al.: Fludarabine, mitoxantrone, dexamethasone (FND)
compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Blood 100 (13): 4351-7, 2002. [PUBMED Abstract]
51. Velasquez WS, Lew D, Grogan TM, et al.: Combination of fludarabine and mitoxantrone in untreated
stages III and IV low-grade lymphoma: S9501. J Clin Oncol 21 (10): 1996-2003, 2003. [PUBMED Abstract]
52. Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular
lymphoma. N Engl J Med 352 (5): 441-9, 2005. [PUBMED Abstract]
file:///Users/mauriciolema/Documents/MLMGuias_09_LinfomaNoHodgkin.webarchive
29/09/11 6:15
Página 39 de 61